VACCINEX, INC. Earnings Per Share Diluted

• VACCINEX, INC. showed an increase of +79.7% in Earnings Per Share Diluted from 2023 to 2024.
• This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2021: $0.21 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $0.12 (loss) per share | Q2 2022: $0.13 (loss) per share | Q3 2022: $1.67 (loss) per share | Q1 2023: $20.89 (loss) per share | Q2 2023: $24.54 (loss) per share | Q3 2023: $15.25 (loss) per share | Q1 2024: $2.94 (loss) per share | Q2 2024: $3.10 (loss) per share | Q3 2024: $2.83 (loss) per share.
• Over the full 4 years of available data (2021 to 2024), VACCINEX, INC.'s Earnings Per Share Diluted has declined by 1,038.5%.
• Historical annual values: Fiscal year 2024: $8.88 (loss) per share | Fiscal year 2023: $43.68 (loss) per share | Fiscal year 2022: $98.05 (loss) per share | Fiscal year 2021: $0.78 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026